Dr. Xiulian Sun

Dr. Sun is the Founder and Chief Technical Officer at uBriGene Biosciences Inc. She is a seasoned healthcare executive with over 10 years of experience in the commercialization of viral vectors, research, drug development, and manufacturing. As the founder, she led the technical team to to build GMP systems including GMP-compliant vectors construction for gene therapy, manufacturing and purification technology, cell line establishment and screening technology, etc. She also led the development of CAR-T technology, especially ICAR30 T cells for Hodgkin lymphoma, and filed an international patent application under the PCT to obtain independent protection of intellectual property. Previously, as co-founder and chief scientist of Vigene Biosciences Inc., Dr. Sun oversaw the commercialization of human gene banks, gene editing technology platform and virus packaging platform. She led the scientific research and technical teams to build and establish GMP production and purification technology platform for cells and gene drug carriers, and spearheaded the development and preparation of multiple GMP plasmids, viral vectors, and CAR-T products. Under her leadership, Vigene Biosciences has completed the construction of 17,000 human genomic libraries, HEK 293 cell libraries, antibody expression and protein purification systems, and became one of the most renowned viral vector suppliers for research (Vigene was acquired by Charles River for US$35 million in May 2021). She has successfully applied for and obtained over 10 patents and has extensive experience in the development of gene therapy vectors and mass production. Dr. Sun studied and worked at The School of Medicine, Nankai University, Institute of Hematology and Blood Diseases, Chinese Academy of Sciences. She holds a PhD from the University of British Columbia (UBC), Faculty of Medicine. Over the past 10 years, she has served as the Deputy Director of the State Key Laboratory, Professor and PhD Supervisor at Qilu Hospital of Shandong University. In addition, she is the recipient of a number of awards and fellowships, including the prestigious title of First Distinguished Taishan Scholar, for her contribution to scientific and technological innovations. Having led four projects with National Natural Science Foundation of China, Dr. Sun has been awarded the Second Prize of the National Science and Technology Progress Award, the International Brain Research Organization (IBRO) Conference Award, and the Age Plus Award of the Canadian Academy of Health Sciences successively. She published over 30 academic papers in PNAS, JEM and other internationally renowned journals which have been cited more than 1000 times. She is the only member in Greater China amongst 14 members of USP AAV Expert Panel.